Susan Combs Scott, MD (@susanscottmd) 's Twitter Profile
Susan Combs Scott, MD

@susanscottmd

Thoracic Medical Oncologist at Johns Hopkins at Sibley @hopkinskimmel @sibleyonline

ID: 1173641438

calendar_today13-02-2013 02:15:54

384 Tweet

850 Followers

498 Following

Bruna Pellini, MD (@brunapellini) 's Twitter Profile Photo

🚨Why should we study circulating tumor DNA (ctDNA)?🧬 Discover how my research on #ctDNA aims to uncover cancer drivers, enable earlier diagnosis, and pave the way for new treatments 💉💊 ⁦Moffitt Cancer Center⁩ ⁦Moffitt Research⁩ #Womeninresearch #NSCLC #MoffittAmbassadors

Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

Congratulations to Dr. Julie Brahmer Dr. Julie Brahmer - this year’s Paul A. Bunn Jr. Scientific Award winner for lifetime achievement and we’re ready to celebrate at #WCLC24!

Congratulations to Dr. Julie Brahmer <a href="/JulieBrahmer/">Dr. Julie Brahmer</a> - this year’s Paul A. Bunn Jr. Scientific Award winner for lifetime achievement and we’re ready to celebrate at #WCLC24!
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

First-line treatment for #EGFR NSCLC is more complex, with approvals for osimertinib (FLAURA), osi + chemo (FLAURA2), and amivantamab + lazertinib (MARIPOSA). Dr. Susan Combs Scott, MD at #DCLung24 highlights the space. Will we see a significant OS improvement?

First-line treatment for #EGFR NSCLC is more complex, with approvals for osimertinib (FLAURA), osi + chemo (FLAURA2), and amivantamab + lazertinib (MARIPOSA). Dr. <a href="/SusanScottMD/">Susan Combs Scott, MD</a> at #DCLung24 highlights the space. Will we see a significant OS improvement?
Dr. Estela Rodriguez (@latinamd) 's Twitter Profile Photo

#WLC25 Susan Combs Scott, MD Johns Hopkins Thoracic Oncology knocked it out of the park⚾️🏟️winning 🥇argument that osimertinib monotherapy is no longer the 2025 standard for 1L EGFR+ NSCLC (highlighting FLAURA2 & MARIPOSA trials) EGFR Resisters #lcsm PER

#WLC25 <a href="/SusanScottMD/">Susan Combs Scott, MD</a> <a href="/HopkinsThoracic/">Johns Hopkins Thoracic Oncology</a> knocked it out of the park⚾️🏟️winning 🥇argument that osimertinib monotherapy is no longer the 2025 standard for 1L EGFR+ NSCLC (highlighting FLAURA2 &amp; MARIPOSA trials) <a href="/EGFRResisters/">EGFR Resisters</a> #lcsm <a href="/gotoPER/">PER</a>
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

#TexasLung25 Dr. Xiuning Le MD PhD sets the stage by discussing 1L therapy in #EGFR NSCLC, comparing and contrasting various strategies available to our patients with advanced disease.

#TexasLung25 Dr. <a href="/LeXiuning/">Xiuning Le MD PhD</a> sets the stage by discussing 1L therapy in #EGFR NSCLC, comparing and contrasting various strategies available to our patients with advanced disease.
Balazs Halmos (@balazshalmosmd) 's Twitter Profile Photo

Mariam Alexander Eric K. Singhi, MD TLC Conference Stephen V Liu, MD Zosia Piotrowska Joel W. Neal, MD, PhD Susan Combs Scott, MD Susie is a legend and OS for the win indeed- ami/lazer does take some extra effort but unprecedented median OS>4 yrs makes it compelling! Now our patients need a companion bag for the extra meds/creams with it - so by popular demand i re-designed my original hefty ami/lazer

<a href="/MariamAlex26/">Mariam Alexander</a> <a href="/lungoncdoc/">Eric K. Singhi, MD</a> <a href="/TLCconference/">TLC Conference</a> <a href="/StephenVLiu/">Stephen V Liu, MD</a> <a href="/ZPiotrowskaMD/">Zosia Piotrowska</a> <a href="/JoelNealMD/">Joel W. Neal, MD, PhD</a> <a href="/SusanScottMD/">Susan Combs Scott, MD</a> Susie is a legend and OS for the win indeed- ami/lazer does take some extra effort but unprecedented median OS&gt;4 yrs makes it compelling!

Now our patients need a companion bag for the extra meds/creams with it - so by popular demand i re-designed my original hefty ami/lazer
OncLive.com (@onclive) 's Twitter Profile Photo

✨EXCLUSIVE✨: Lung cancer experts discuss the evolving use of antibody-drug conjugates in non–small cell lung cancer. Dr. Estela Rodriguez Tarek mekhail Balazs Halmos Susan Combs Scott, MD Dr. Julie Brahmer Corey Langer Benjamin Levy #lcsm #oncology Sign up to watch! onclive.com/view/lung-canc…

Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

Aakash Desai, MD, MPH, FASCO JTO & JTO CRR LungCancerRx 🫁💊 OncoDaily Thanks for sharing this, Aakash Desai, MD, MPH, FASCO! Just yesterday we were talking about this with Susan Combs Scott, MD! Curious, any subgroup analysis on the use of dual checkpoint vs single agent IO or IO + Chemo (as in melanoma, these patients often get dual ICI upfront) Stephen V Liu, MD Allison Betof Warner, MD, PhD?

Susan Combs Scott, MD (@susanscottmd) 's Twitter Profile Photo

Join me and a distinguished roster of renowned experts at the D.C. Lung Cancer Conference 2025! This conference will focus on practical, up-to-date strategies for clinicians from all disciplines who care for patients with Lung Cancer. Register today at medstarhealth.org/dclung25

Join me and a distinguished roster of renowned experts at the D.C. Lung Cancer Conference 2025! This conference will focus on practical, up-to-date strategies for clinicians from all disciplines who care for patients with Lung Cancer. Register today at medstarhealth.org/dclung25
Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

Treatment Algorithm series: mNSCLC w/ actionable mutations in 1L with Susan Combs Scott, MD ✅ EGFR ✅ ALK ✅ ROS1/BRAF/RET/NTRK/MetExon14 Full discussion: ⭐️ oncbrothers.com/nsclc-targeted… ⭐️ “Oncology Brothers” podcast #lcsm #OncTwitter #LungCancer OncUpdates

Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

Treatment Algorithm: This is the algorithm we have use during our discussion w/ Susan Combs Scott, MD for mNSCLC with potential actionable mutation in 1L! #OncTwitter #MedTwitter #lcsm

Treatment Algorithm: This is the algorithm we have use during our discussion w/ <a href="/SusanScottMD/">Susan Combs Scott, MD</a> for mNSCLC with potential actionable mutation in 1L! 

#OncTwitter #MedTwitter #lcsm
OncLive.com (@onclive) 's Twitter Profile Photo

We asked 5 top lung cancer experts which #ASCO2025 presentations are a must-see—and why. 🎙️ Featuring: Joshua Sabari, MD, Sandip Patel MD FASCO, Susan Combs Scott, MD, Desai, & Qin 👉 Get their picks—sign up for exclusive access! hubs.li/Q03nrrcy0

Deborah Doroshow (@ddoroshow) 's Twitter Profile Photo

As my thoughtful colleagues provide advice for #ASCO25 attendees, here’s a list of stupid stuff to avoid (guilty as charged) #fiASCO 1. Wearing cute shoes. Just no. 2. Scheduling meetings in the right time zone-I screw this up and have overlapping meetings at least once a year